US FDA Approves First Treatment for Rare Genetic Disease
- Food and Drug Management (FDA) on Wednesday approved Soleno Therapeutics' drug for the treatment of Prader-Willi syndrome (PWS), a rare genetic disease.This marks the first available treatment for...
- The drug, vykat XR, is approved for treating Prader-Willi syndrome, a genetic disorder resulting from deletions on chromosome 15. These deletions affect gene expression regulation.
- PWS affects approximately 50,000 people in the United States.
FDA Approves First treatment for Prader-Willi Syndrome
Table of Contents
- FDA Approves First treatment for Prader-Willi Syndrome
- FDA Approves First Treatment for Prader-Willi syndrome
- Frequently Asked Questions About Prader-Willi syndrome Treatment
- What is Prader-Willi Syndrome?
- What causes Prader-Willi Syndrome?
- What is vykat XR and what does it treat?
- What is hyperphagia, and how does it relate to Prader-Willi Syndrome?
- What are the health risks associated with Prader-Willi Syndrome?
- When will Vykat XR be available in the U.S.?
- What was the approval process for Vykat XR?
- Key Features of Vykat XR
- Summary of Key Data
- Frequently Asked Questions About Prader-Willi syndrome Treatment
Published: March 26, 2025
The U.S. Food and Drug Management (FDA) on Wednesday approved Soleno Therapeutics’ drug for the treatment of Prader-Willi syndrome (PWS), a rare genetic disease.This marks the first available treatment for patients experiencing intense and persistent hunger.
Trading of the company’s shares was temporarily halted.
Vykat XR Approved for PWS
The drug, vykat XR, is approved for treating Prader-Willi syndrome, a genetic disorder resulting from deletions on chromosome 15. These deletions affect gene expression regulation.
About Prader-Willi Syndrome
PWS affects approximately 50,000 people in the United States. The condition impacts nutrition, behavior, and mood, and slows physical and intellectual advancement. Symptoms are often apparent at birth, with infants exhibiting low muscle tone and difficulty breastfeeding.
Hyperphagia: A Key Symptom
As children with PWS age, they develop hyperphagia, characterized by an insatiable hunger that persists even after eating. This symptom can emerge as early as age 4,typically around age 8,and continues into adulthood.
Health Risks Associated with PWS
Uncontrolled appetite can lead to rapid weight gain, resulting in obesity, breathing difficulties, and heart disease.
The company estimates the average lifespan of individuals with PWS to be between 21 and 29 years.
Availability
Soleno Therapeutics anticipates that Vykat XR will be available in the U.S. starting in April 2025 for patients aged 4 years and older with PWS who exhibit hyperphagia.
Approval Process
The approval follows a lengthy FDA review process and conflicting results from an advanced phase study on the drug’s effectiveness.
FDA Approves First Treatment for Prader-Willi syndrome
Published: March 26, 2025
The U.S.Food and Drug Administration (FDA) approved Soleno Therapeutics’ drug for the treatment of Prader-Willi syndrome (PWS), a rare genetic disease. This marks the first available treatment for patients experiencing intense and persistent hunger.
Trading of the company’s shares was temporarily halted.
Frequently Asked Questions About Prader-Willi syndrome Treatment
What is Prader-Willi Syndrome?
Prader-Willi syndrome (PWS) is a rare genetic disorder impacting numerous aspects of an individual’s life. It affects approximately 50,000 people in the United States. The condition impacts nutrition, behavior, and mood, and slows physical and intellectual advancement. Symptoms are frequently enough apparent at birth, with infants exhibiting low muscle tone and difficulty breastfeeding.
What causes Prader-Willi Syndrome?
PWS results from deletions on chromosome 15. These deletions affect gene expression regulation.
What is vykat XR and what does it treat?
Vykat XR, developed by Soleno Therapeutics, is the first treatment approved for Prader-Willi syndrome. It is designed to treat the intense and persistent hunger (hyperphagia) associated with PWS.
What is hyperphagia, and how does it relate to Prader-Willi Syndrome?
Hyperphagia, characterized by an insatiable hunger that persists even after eating, is a key symptom of PWS. It can emerge as early as age 4, typically around age 8, and continues into adulthood.
What are the health risks associated with Prader-Willi Syndrome?
Uncontrolled appetite, a hallmark of PWS, can lead to rapid weight gain, resulting in obesity, breathing difficulties, and heart disease. The company estimates the average lifespan of individuals with PWS to be between 21 and 29 years.
When will Vykat XR be available in the U.S.?
Soleno Therapeutics anticipates that Vykat XR will be available in the U.S. starting in April 2025 for patients aged 4 years and older with PWS who exhibit hyperphagia.
What was the approval process for Vykat XR?
The approval followed a lengthy FDA review process and conflicting results from an advanced phase study on the drug’s effectiveness.
Key Features of Vykat XR
Vykat XR is approved specifically to address hyperphagia,a significant challenge for individuals with PWS,helping manage uncontrolled appetite and improving overall health outcomes.
Summary of Key Data
The following table summarizes key aspects of the newly approved PWS treatment.
| Feature | Details |
|---|---|
| Drug Name | Vykat XR |
| Approved for | Treatment of hyperphagia in Prader-Willi syndrome |
| Target Population | Individuals aged 4 years and older with PWS who exhibit hyperphagia |
| Expected Availability | April 2025 (in the U.S.) |
| Primary Benefit | Addresses insatiable hunger,potentially improving weight management and related health outcomes |